The main aim of treatment of opiate dependence is complete abstinence. However, opiate dependence treatment is an extremely difficult disease to treat.
Treatment of drug dependence is a difficult multi-aspect process, and this treatment does not always result in a stable remission.
In European Union substitution therapy (ST) is mainly used in treatment of opiate dependence.
For this purpose opiate receptor agonists (methadone therapy - MT, buprenorphine) are used. Substitution therapy has a number of drawbacks: Methadone related deaths, growth of methadone dependence, and misuse of buprenorphine which made a buprenorphine abuse and dependence a serious problem in Finland in particular.
Ultimate ST aim is to prepare a patient for a life without opiates.
The most effective method providing a stable abstinence is the treatment with opioid antagonists (OA). In the European Union currently available OA include only oral formulations.
The main problem of these medicinal forms is a poor compliance: Patients are not taking these medication as prescribed.
Long-acting medications is the best and easiest way to solve the problem of poor compliance.
At present there are no long-acting OA in the European pharmaceutical market.
In the Russian Federation treatment of opiate dependence with officially registered long-acting OA (Vivitrol, Prodetoxone) for 1-4 months are widely used because substitution therapy is legally prohibited.
NOVOERG offers highly professional, effective treatment of opiate dependence in Russia, St.-Petersburg.
NOVOERG provides gathering and supply of patients with the information necessary for treatment, renders service on patients transfer.